Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Esperion Therapeutics
Medpace, Inc.
Information provided by (Responsible Party):
Esperion Therapeutics
ClinicalTrials.gov Identifier:
First received: February 24, 2014
Last updated: April 3, 2014
Last verified: April 2014

The purpose of this research study is to see how ETC-1002 is tolerated in the body and how ETC-1002 affects the levels of LDL-C (bad cholesterol) in patients receiving ongoing statin therapy.

Condition Intervention Phase
Drug: ETC-1002
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of ETC-1002 Versus Placebo in Patients With Hypercholesterolemia Receiving Ongoing Statin Therapy

Resource links provided by NLM:

Further study details as provided by Esperion Therapeutics:

Primary Outcome Measures:
  • Percent change from baseline in calculated low density lipoprotein-cholesterol (LDL-C) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percent change in non-high-density lipoprotein cholesterol (non-HDL-C) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Percent change in apolipoprotein B (ApoB) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Percent change in total cholesterol (TC) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Percent change in high-sensitivity C-reactive protein (hsCRP) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Percent change in triglycerides (TG) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Percent change in lipoprotein particle number [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Safety using adverse event reports; clinical laboratory results [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Safety using adverse event reports; vital signs [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Pharmacokinetic plasma trough concentrations of ETC-1002 and metabolite 15228 [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 132
Study Start Date: February 2014
Estimated Study Completion Date: March 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ETC-1002 120 mg/day
Orally, once daily in morning as capsules
Drug: ETC-1002 Drug: Placebo
Experimental: ETC-1002 180 mg/day
Orally, once daily in morning as capsules
Drug: ETC-1002
Placebo Comparator: Placebo
Orally, once daily in morning
Drug: Placebo

Detailed Description:

Approximately 132 hypercholesterolemic patients already taking statin therapy to treat elevated LDL-C will be randomized in a ratio of 1:1:1 to receive either ETC-1002 (120 mg or 180 mg dose), or placebo for 12 weeks in addition to ongoing statin therapy. This study will explore the safety and efficacy of ETC-1002 when given to patients receiving statin therapy.


Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Fasting, calculated mean LDL-C ≥130 mg/dL and ≤220 mg/dL
  • Fasting mean TG level ≤400 mg/dL
  • Stable statin therapy for at least 3 months prior to screening: atorvastatin (10 or 20 mg daily), simvastatin (5, 10 or 20 mg daily), rosuvastatin (5 or 10 mg daily), or pravastatin (10, 20 or 40 mg daily)

Exclusion Criteria:

  • Clinically significant cardiovascular disease within 12 months of screening
  • Current muscle-related symptoms that may be due to ongoing statin therapy or a history of certain lab abnormalities that occurred during statin therapy and resolved when statin therapy was discontinued
  • Type 1 diabetes or uncontrolled type 2 diabetes
  • Use of metformin or thiazolidinediones (TZD) within 4 weeks of screening
  • History of chronic musculoskeletal symptoms such as fibromyalgia
  • Uncontrolled hypothyroidism
  • Liver disease or dysfunction
  • Renal dysfunction or nephritic syndrome
  • Gastrointestinal conditions or procedures or surgeries
  • Hematologic or coagulation disorders or low hemoglobin levels
  • HIV or AIDS
  • History of malignancy
  • History of drug or alcohol abuse within 2 years
  • Use of experimental or investigational drugs within 30 days of screening
  • Use of ETC-1002 in a previous clinical study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02072161

Contact: Jeffrey C Hanselman clinicaltrials@esperion.com
Contact: Janice R Margulies clinicaltrials@esperion.com

  Show 27 Study Locations
Sponsors and Collaborators
Esperion Therapeutics
Medpace, Inc.
Study Director: Diane E MacDougall Esperion Therapeutics
  More Information


Responsible Party: Esperion Therapeutics
ClinicalTrials.gov Identifier: NCT02072161     History of Changes
Other Study ID Numbers: 1002-009
Study First Received: February 24, 2014
Last Updated: April 3, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Esperion Therapeutics:

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on September 02, 2015